Literature DB >> 22065271

Myocardial infarction associated with use of the synthetic cannabinoid K2.

Arshid Mir1, Adebisi Obafemi, Amy Young, Colin Kane.   

Abstract

Designer drugs have been problematic over the years. Products such as K2 and Spice, which contain synthetic cannabinoids, are marketed as incense and are widely available on the Internet and at various specialty shops. The effects are reported as cannabis-like after smoking them. In addition, use of these synthetic cannabinoids will not appear on a routine urine toxicology screen. Recently, K2 became a popular alternative to marijuana among youths. Health implications of these designer drugs are not completely understood. Little has been reported about the harmful effects of K2. We report here the first (to our knowledge) cases of myocardial infarction (MI) after smoking K2. Three patients presented separately to the emergency department complaining of chest pain within days after the use of K2. Acute MI was diagnosed in each case on the basis of electrocardiogram changes and elevated troponin levels. Coronary angiography was performed, and the results were normal for the first 2 patients. The incidence of ST-elevation MI is low among teenagers, and association with drug use should be suspected. Public education and awareness need to be heightened about the possible health implications of K2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065271     DOI: 10.1542/peds.2010-3823

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  67 in total

1.  K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.

Authors:  Rita G McKeever; David Vearrier; Dorian Jacobs; Gregory LaSala; Jolene Okaneku; Michael I Greenberg
Journal:  J Med Toxicol       Date:  2015-03

Review 2.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 3.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

4.  "K2/Spice": have you updated your differentials? A case report.

Authors:  Roopa Sethi; Neha Thapa; Ashwini Saxena; Ritu Chahil
Journal:  Prim Care Companion CNS Disord       Date:  2013

Review 5.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

6.  Diagnostic role of strain imaging in atypical myocarditis by echocardiography and cardiac MRI.

Authors:  Bethany L Wisotzkey; Brian D Soriano; Erin L Albers; Mark Ferguson; Sujatha Buddhe
Journal:  Pediatr Radiol       Date:  2018-04-13

Review 7.  What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products? A Systematic Review.

Authors:  Emilie Jouanjus; Valentin Raymond; Maryse Lapeyre-Mestre; Valérie Wolff
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

Review 8.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

9.  High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use.

Authors:  Sameir Alhadi; Anupama Tiwari; Rais Vohra; Roy Gerona; Janak Acharya; Kathryn Bilello
Journal:  J Med Toxicol       Date:  2013-06

10.  AKI associated with synthetic cannabinoids: a case series.

Authors:  Gautam Kantilal Bhanushali; Gaurav Jain; Huma Fatima; Leah J Leisch; Denyse Thornley-Brown
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-14       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.